• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
β-Nicotinamide adenine dinucleotide phosphate
L-Tyrosine
DL-Menthol
Calcium stearate
Collagen Tripeptide
Mirogabalin

Lupin launches generic Namenda XR capsules in the US

biospectrumasiaFebruary 26, 2018

Tag: lupin , US , Namenda XR capsules

Pharma major Lupin announced the launch of its Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, 28mg having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Memantine Hydrochloride ER capsules 7mg, 14mg, 21mg, 28mg are the generic equivalents of Allergan’s Namenda XR® capsules. It is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type.

Memantine Hydrochloride ER capsules 7mg, 14mg, 21mg, 28mg had annual sales of approximately USD 936 million in the US (IQVIA MAT December 2017).

Register as Visitor to CPhI China 2018!

Previous:Merck invests additional €40 M to enhance services in Asia

Next:PharmaJet unites with Genexine to develop DNA vaccine

Related News

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

Lupin launches generic Namenda XR capsules in the US | Pharmasources.com

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

MetP Pharma AG today announced tirzepatide in a BrainDos™ formulation reduced pro-inflammatory cytokine Il-6 by more than 80% and 2-fold stronger than with aqueous tirzepatide solution.

You may like
More>>

A202 Sausage Labeling System

A202 Sausage Labeling System
Dust Free Cleanroom GMP Pharmaceutical Modular Clean Room System for Semiconductor/Precision Electro

Dust Free Cleanroom GMP Pharmaceutical Modular Clean Room System for Semiconductor/Precision Electro
30*30cm Super Absorbency Customizable Cleaning Cloth

30*30cm Super Absorbency Customizable Cleaning Cloth
Gold Supplier Citrus Aurantium Extract Hesperidin

Gold Supplier Citrus Aurantium Extract Hesperidin
Nose Actuator（KRT-11 Nose Used）

Nose Actuator（KRT-11 Nose Used）
Sodium dihydrogen phosphate dihydrate USP28

Sodium dihydrogen phosphate dihydrate USP28
Crocus sativus

Crocus sativus
Chromium Picolinate USP

Chromium Picolinate USP
99% up by HPLC USP GMP DMF Sorafenib tosylate 475207-59-1

99% up by HPLC USP GMP DMF Sorafenib tosylate 475207-59-1
Psyllium Husk P.E

Psyllium Husk P.E

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service